Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. is one of the world's largest independent biotechnology companies, developing biologic therapies that address serious illnesses across oncology, cardiovascular disease, inflammation, and other therapeutic areas. The company's news flow reflects its position as a major pharmaceutical innovator, with developments spanning regulatory approvals, clinical trial results, financial performance, and strategic initiatives.
Following Amgen's news provides insight into the biotechnology sector's evolution and the regulatory pathway for bringing complex biologic therapies to market. The company regularly announces FDA decisions on new therapies and expanded indications for existing products, offering real-time visibility into which treatments are gaining regulatory approval and market access. Clinical trial data releases reveal the company's research progress across its development pipeline, while earnings reports detail financial performance across geographic markets and product portfolios.
Amgen's announcements frequently include updates on cardiovascular therapies targeting cholesterol management, oncology supportive care products, and treatments for inflammatory conditions and bone health disorders. The company also announces manufacturing expansions that signal investment in biomanufacturing capacity and strategic moves including acquisitions, partnerships, and licensing agreements that shape its therapeutic portfolio. Investor presentations and analyst conferences provide management's perspective on business priorities and market dynamics affecting the broader biologics sector.
This news feed aggregates material disclosures, regulatory milestones, and corporate developments specific to Amgen, providing a centralized resource for tracking one of biotechnology's pioneering companies as it navigates an increasingly competitive landscape shaped by biosimilar competition, pricing pressures, and evolving therapeutic approaches.
Amgen has appointed Michael V. Drake, M.D., to its Board of Directors, effective immediately, bringing the board's total to 13 members, 12 of whom are independent. Dr. Drake, currently the president of the University of California system, has prior leadership experience at The Ohio State University and UC Irvine. His extensive background in medicine and academia is expected to enhance Amgen's innovation efforts in treating serious illnesses.
Amgen has declared a $1.94 per share dividend for the third quarter of 2022, payable on September 8, 2022. Stockholders on record by August 18, 2022 will receive this dividend. As a leader in biotechnology, Amgen focuses on developing innovative therapeutics for serious illnesses through advanced human genetics. The company’s commitment to health outcomes has made it a significant player in the Dow Jones Industrial Average and Nasdaq-100 index.
Amgen will host a webcast for investors on August 8, 2022, at 12:00 p.m. ET, during the IASLC 2022 World Conference on Lung Cancer. David M. Reese, M.D., will present data on LUMAKRAS® (sotorasib) used alongside immunotherapy and a SHP2 inhibitor for treating non-small cell lung cancer, plus findings on tarlatamab for small cell lung cancer. The webcast will be available for replay for 90 days post-event. More details can be found on Amgen's website.
Amgen will report its second quarter financial results on August 4, 2022, after U.S. market close. A conference call with senior management, including CEO Robert A. Bradway, is scheduled for 2:00 p.m. PT. The call will be accessible via live audio broadcast online and will be archived for at least 90 days. Amgen, a leader in biotechnology since 1980, is focused on serious illnesses and is part of the Dow Jones Industrial Average and Nasdaq-100. The company is recognized for its significant contributions to health and was named one of the 25 World's Best Workplaces™.
The Amgen Foundation has announced a significant increase in its investment in LabXchange, an online science education platform, by more than doubling its initial funding to a total of $30 million. This initiative, in partnership with Harvard's Vice Provost of Advances in Learning, aims to enhance access to quality science education for students and educators globally. LabXchange, which has registered 20 million users across 230 countries, plans to expand its offerings, including content in multiple languages and addressing inequities in STEM education.
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 43rd Annual Healthcare Conference on June 15, 2022, at 1:40 p.m. ET. Key executives, David M. Reese and Peter H. Griffith, will discuss the company's developments. The event will be accessible via a live webcast for media, investors, and the public, and will be archived for 90 days post-event.
Amgen is a leading biotechnology company focused on serious illnesses, with a robust pipeline and a commitment to improving health outcomes.
Amgen announced FDA approval for RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, for treating adults with moderate to severe rheumatoid arthritis (RA) who have not responded to TNF antagonist therapies. RIABNI is already approved for several conditions, including Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. The clinical study showed RIABNI's efficacy and safety are equivalent to Rituxan. This move enhances Amgen's portfolio of biosimilars, reinforcing its commitment to affordable treatment options.
Amgen and Takeda have presented data from the Phase 3 PARADIGM trial at ASCO 2022, demonstrating the efficacy of Vectibix (panitumumab) over bevacizumab in treating unresectable wild-type RAS metastatic colorectal cancer. The trial involved 823 chemotherapy-naive patients and revealed significant improvements in overall survival (OS) with Vectibix, showcasing median OS rates of 37.9 vs. 34.3 months for left-sided tumors. Vectibix's safety profile aligns with previous studies. These results reinforce Vectibix's role as a standard first-line therapy in this patient population.
Amgen will present at the 2022 Jefferies Healthcare Conference on June 8, 2022, at 9:30 a.m. ET. Murdo Gordon, Amgen's executive vice president of Global Commercial Operations, will lead the presentation, which will be webcast for the media, investors, and the public. The event highlights Amgen's commitment to innovation in biotechnology and advanced human genetics. The webcast will be available for replay for 90 days post-event on Amgen's official website.
Amgen announced positive topline results from its Phase 2 OCEAN(a)-DOSE study, revealing that olpasiran, an investigational treatment, successfully reduced Lipoprotein(a) levels by over 90% in many patients at weeks 36 and 48. The trial involved 281 adult patients with elevated Lp(a) levels and atherosclerotic cardiovascular disease. No new safety issues were reported, and the results are expected to be presented at a future medical congress. These findings could provide new options for patients with limited treatment alternatives for elevated Lp(a).
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
